Roche: research agreement with US group Harpoon
(CercleFinance.com) - Harpoon Therapeutics, a San Francisco-based biotech company, announced on Monday that it has signed a research agreement with Swiss pharmaceutical giant Roche.
Under the terms of the agreement, Roche will provide Harpoon with its Tecentriq immunotherapy for a clinical trial program involving HPN328, the Californian company's most advanced candidate.
This aims to assess the efficacy of a combination of both molecules in the treatment of solid tumours, in particular non-small cell cancer.
These clinical studies will be sponsored by Harpoon, with Roche simply supplying the company with atezolizumab.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Under the terms of the agreement, Roche will provide Harpoon with its Tecentriq immunotherapy for a clinical trial program involving HPN328, the Californian company's most advanced candidate.
This aims to assess the efficacy of a combination of both molecules in the treatment of solid tumours, in particular non-small cell cancer.
These clinical studies will be sponsored by Harpoon, with Roche simply supplying the company with atezolizumab.
Copyright (c) 2022 CercleFinance.com. All rights reserved.